Preventing Temperature Abuse - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Preventing Temperature Abuse
Innovations protect the quality of temperature-sensitive products.


Pharmaceutical Technology
Volume 35, Issue 2, pp. 34-37


The International Air Transport Association's time- and temperature-sensitive label. (PHOTO IS COURTESY OF THE INTERNATIONAL AIR TRANSPORT ASSOCIATION)
A large, compressor-based heating–cooling unit capable of maintaining a temperature-controlled environment for five European-sized or four US-sized pallets recently received an airworthiness certification from EASA. It maintains internal temperature between 0 and 25 °C in ambient conditions ranging from –25 to 50 °C (RAP e2 container, Envirotainer).

A passive pallet-shipper system for full or half pallets provides thermal protection for more than 120 h (i.e., five days) without requiring any power. The design relies on phase-change material and vacuum-insulated panels. The reusable system provides a 48 × 40 × 52-in. space with a payload capacity of 890 L (31.4 ft3 ) or a 48 × 40 × 30-in. area that holds 406 L (14.3 ft3 ) (Credo Xtreme pallet shipper, MTS). The pallet shipper is part of a range of reusable thermal containers (Credo Cube) that are used by the largest temperature-controlled healthcare transportation provider in Canada (ATS Healthcare).

Another passive system consists of a lockable trunklike unit that is durable, reusable, and compatible with security scanning. Capable of maintaining temperatures between 2 and 8 °C for as long as five days, the system is available with payloads of 36 L (1.27 ft3 ) and 11 L (0.4 ft3 ). An optional data logger records downloadable internal and external temperature data to show whether the internal temperature remained in spec throughout the shipment's travels (Kodiak Active Temperature Control Shipping Containers, Active CC Boxes).

A similar reusable design with handles and a latch relies on plant-based phase-change technology and encapsulated vacuum-insulated panels to boost performance while reducing weight. The passive temperature-controlled system produces about seven times the insulating effects of common alternatives such as expanded polystyrene and polyurethane (OrcaTherm temperature-controlled packaging, Intelsius).

For less stringent applications, a passive system maintains an 11 × 11 × 5.5-in. (0.4 ft3 ) payload area in the 2–8 °C range for 72 h. It consists of gel packs, expanded polystyrene (EPS) panels, and an outer plastic or corrugated case. The unit holds 1 to 7.5 lb of product (TimeSaver 72, Cryopak). All components of the packaging are recyclable, and the EPS insulating panels contain as much as 20% postindustrial recycled content.

Another advantage of the design, which won a Greener Package Award in 2010 from Summit Publishing, is the energy- and time-saving nature of the phase-change material used as the core refrigerant. It freezes and thaws at 5 °C and does not need to be pre-conditioned in a refrigerator or freezer (Engineered Phase 5 phase-change material, Cryopak).

For smaller quantities that are delivered quickly, an inflatable thermal envelope maintains the contents between 2 and 8 °C for as long as 24 hours. Patented construction blocks heat transfer and cushions the product, too. Delivered inflated, the reusable pouch features a zipper closure and dual compartments: one for product, and one for cooling-gel packs. It's available in 1-, 3-, and 5-L sizes (One Day pharmaceutical pouch, Coldpack).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here